lilly glp 1 Diabetes Patients Also Struggle to Access GLP-1 Agonists Lilly is now pharma's top
Description
The GLP-1 receptor agonist market has been characterized by robust expansion as demand for effective therapies for type 2 diabetes and obesity has increased steadily
B.HyotylainenT.NielsenT.JensenB
It remains to be seen what share of the costs of weight-loss drugs will be borne by patients or payers
Vials of assay-ready cells were rapidly thawed from cryopreservation on the day of the assay
